Exploring the Potential Drug Target ATP2A2: Unlocking the Switch for Slow Twitch Skeletal Muscle Isoform

Target Name: ATP2A2

NCBI ID: G488

ATP2A2

Exploring the Potential Drug Target ATP2A2: Unlocking the Switch for Slow Twitch Skeletal Muscle Isoform

Introduction

ATP2A2, also known as slow twitch skeletal muscle isoform, is a protein that plays a crucial role in muscle function. It is a subunit of the ATPase enzyme, which is responsible for regulating the ATP energy released by the muscle during contractions. slow twitch ske joint muscle isoform ATP2A2: Exploring the Potential Drug Target (Or Biomarker) _ copy. slow twitch skeletal muscle isoform ATP2A2: Exploring the Potential Drug Target (Or Biomarker) slow twitch skeletal muscle isoform ATP2A2 in Exploring the Potential Drug Target point (or biomarker)_copy.

Background

Muscle contraction is a fundamental process that allows animals to move and maintain posture. The muscle contraction process involves the interaction between the muscle fibers, ATPase enzymes, and other molecular mechanisms. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target ( (or biomarker)_copy. Slow twitch skeletal muscle isoform ATP2A2 in exploring potential drug targets (or biomarker)_copy.

Recent studies have shed light on the role of ATPase enzymes in muscle contraction. In particular, the slow twitch skeletal muscle isoform ATP2A2 (ATP2A2 ) has emerged as a promising drug target due to its unique function in muscle contraction. Slow twitch skeletal muscle isoform ATP2A2 is exploring potential drug targets (or biomarkers)_Copy.

Drug Targets and Biomarkers

ATP2A2 has been identified as a potential drug target due to its role in muscle contraction and its expression in various muscle fibers. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_Copy. Studies have shown that inhibiting ATP2A2 function can lead to muscle weakness and decreased force production during exercise. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_Copy.

In addition to its function in muscle contraction, ATP2A2 has also been linked to the regulation of muscle mass and muscle fiber composition. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker). These studies have suggested that modulating ATP2A2 activity may be a valuable approach to treat muscle-related diseases. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_Copy.

Biomarkers

The identification of biomarkers for drug targets is an essential step in the development of new treatments. One of the most promising biomarkers for ATP2A2 is the Ki67 enzyme, which is often used as a marker for muscle fiber damage. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_copy.

Ki67 is a protein that is expressed in muscle fibers and is involved in the regulation of cell growth and differentiation. Studies have shown that Ki67 expression is significantly increased in muscles after exercise, indicating that it may be a useful biomarker for tracking muscle damage caused by exercise. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_copy.

Another biomarker that has been associated with ATP2A2 is the myosin ATPase (MyosATP), which is a protein that plays a crucial role in muscle contraction. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_ Copy. MyosATP is involved in regulating the ATPase activity, which is essential for muscle contraction. Slow twitch skeletal muscle isoform ATP2A2 is being explored as a potential drug target (or biomarker)_Copy.

Conclusion

In conclusion, the study of ATP2A2 and its potential drug targets has significant implications for the development of new muscle-related treatments. The identification of slow twitch skeletal muscle isoform ATP2A2 and its potential drug targets has significant implications for the development of new muscle-related treatments. of Ki67 and MyosATP as potential biomarkers for ATP2A2 suggests that modulating ATPase activity may be a valuable approach to treating muscle-related diseases. Slow twitch skeletal muscle isoform ATP2A2 in exploring potential drug targets (or biomarkers)_Copy.

Protein Name: ATPase Sarcoplasmic/endoplasmic Reticulum Ca2+ Transporting 2

Functions: This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen (PubMed:16402920, PubMed:12542527). Involved in autophagy in response to starvation. Upon interaction with VMP1 and activation, controls ER-isolation membrane contacts for autophagosome formation (PubMed:28890335). Also modulates ER contacts with lipid droplets, mitochondria and endosomes (PubMed:28890335)

The "ATP2A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP2A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets